Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes

Autor: Marc A. Boogaerts, Ronald Brand, Volker Runde, Jürgen Finke, Jan J. Cornelissen, Enric Carreras, Anja van Biezen, Eliane Gluckman, Andrea Bacigalupo, Antonio Pagliuca, Tapani Ruutu, Dietger Niederwieser, Philippe Guardiola, H. C. Schouten, Theo de Witte, Franco Locatelli
Přispěvatelé: Hematology, Cardiology
Rok vydání: 2002
Předmět:
Adult
Male
medicine.medical_specialty
Adolescent
medicine.medical_treatment
Immunology
Bone Marrow Cells
Hematopoietic stem cell transplantation
Neutropenia
Biochemistry
Gastroenterology
Nuclear Family
Transplantation Immunology
Internal medicine
Granulocyte Colony-Stimulating Factor
medicine
Humans
Child
Survival analysis
Retrospective Studies
business.industry
Histocompatibility Testing
Myelodysplastic syndromes
Hematopoietic Stem Cell Transplantation
Cell Biology
Hematology
Middle Aged
Hematopoietic Stem Cells
medicine.disease
Survival Analysis
Hematopoietic Stem Cell Mobilization
Granulocyte colony-stimulating factor
Transplantation
Transplantation
Isogeneic
Treatment Outcome
medicine.anatomical_structure
International Prognostic Scoring System
Child
Preschool
Myelodysplastic Syndromes
Female
Bone marrow
business
Haematology
Zdroj: Blood, 99, 12, pp. 4370-8
Blood, 99, 4370-8
Blood, 99(2), 4370-4378. American Society of Hematology
ISSN: 1528-0020
0006-4971
Popis: Item does not contain fulltext In this multicenter retrospective study, the outcomes of 234 patients with myelodysplastic syndrome (MDS) who underwent transplantation between 1995 and 1999 from HLA-identical siblings were analyzed according to the hematopoietic stem cell source used, that is, bone marrow (BM, n = 132) or granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells (PBPCs, n = 102). There were 69 cases of refractory anemia (RA), 86 RA with excess blasts (RAEB), 75 RAEB in transformation (RAEB-t), and 4 unclassified MDS at diagnosis. The International Prognostic Scoring System was intermediate-2 or high in 104 of the 158 available scores. Multivariate analyses focused on transplantation-related mortality (TRM), 2-year treatment failure incidence, and survival. Use of PBPCs reduced the median duration of neutropenia and thrombocytopenia by 4 and 12 days, respectively. The incidence of acute GVHD was similar whatever the graft type used. Chronic GVHD was more likely to have occurred with PBPCs (odds ratio [OR], 1.62; 95% confidence interval [CI], 0.87-3.02). Two-year TRM was significantly reduced with PBPCs (relative risk [RR], 0.33; 95% CI, 0.15-0.73; P
Databáze: OpenAIRE
Externí odkaz: